Drug Trial Radar · NCT00377377
Oral Ghrelin Agonist in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: May 3, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Nov 2005
Primary completion
Not stated
Study completion Jul 2006
Sponsor
- Lead sponsor
- University Hospital, Basel, SwitzerlandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 18, 2006
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 30 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
EP01572 is a peptidomimetic growth hormone secretagogue, which has potent GH-releasing activity after intravenous administration.It is an analogue of the natural compound ghrelin. Since an oral delivery system would be preferable in many of the possible therapeutic indications, the pharmacological profile and the GH-releasing activity of increasing single, oral doses of EP01572 in healthy volunteers will be evaluated. In addition, the pharmacokinetics and pharmacological effects of EP01572 will be investigated after intraduodenal administration.
Conditions
- Healthy Subjects
Interventions
EP1572 (ghrelin agonist) oral and duodenal applicationDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Growth hormone release
- Pharmacokinetics
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.